Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $44,743.40. The sale was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $4.73 during trading on Wednesday, reaching $351.61. 669,731 shares of the company’s stock traded hands, compared to its average volume of 498,616. The company has a market capitalization of $15.64 billion, a P/E ratio of 16.62, a PEG ratio of 1.16 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $321.69 and its 200 day moving average is $271.04. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $353.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the previous year, the company posted $5.24 earnings per share. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Co. will post 24.79 EPS for the current year.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $30,000. Rise Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter worth approximately $32,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $33,000. Finally, GAMMA Investing LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $43,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $334.45.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.